There is no verified blanket September 2026 rewrite of feline-vaccine guidelines; the confirmed change is EU authorization of two combination vaccines using self-amplifying RNA particles for feline leukemia virus protection. That matters because it expands vaccine options, while owners should watch local availability and component-specific schedules rather than assume every cat now needs the same shots. The American Animal Hospital Association still identifies its feline guideline as the 2020 AAHA/AAFP guidance, while the World Small Animal Veterinary Association's current global guideline is the 2024 update. September 2026 is therefore a useful checkpoint, not the date of a new universal schedule.
Table of Contents
- What actually changed in 2026?
- How strong is the evidence?
- Which cats should receive FeLV vaccination?
- Does the new combination mean fewer appointments?
- What should owners watch next?
What actually changed in 2026?
The European Union authorized Nobivac NXT HCPFeLV and Nobivac NXT HCPChFeLV on July 29, 2026. The documented product-level change adds self-amplifying RNA-particle FeLV protection to combination cat vaccines, according to the European Union Official Journal authorization. FeLV is feline leukemia virus, an infection that can cause progressive disease.
"Self-amplifying RNA" describes the active vaccine technology; it does not mean the vaccine changes a cat's vaccination needs or guarantees complete protection. The HCPChFeLV product targets five pathogens: FeLV, feline herpesvirus, feline calicivirus, feline panleukopenia virus, and Chlamydia felis. Its combination format may simplify how several vaccine components are delivered, but the protections do not all follow the same timetable.
How strong is the evidence?
The European Medicines Agency described HCPChFeLV as the first veterinary vaccine recommended for EU authorization with self-amplifying RNA as an active substance. Its review covered 15 closed-facility studies and one field study involving 142 cats, as detailed in EMA's April 2026 announcement. The studies found reductions in clinical disease or pathogen shedding for the targeted infections.
That is meaningful, but it is not the same as proving that every vaccinated cat will avoid infection. The distinction is especially important for FeLV, herpesvirus, and calicivirus. Vaccination reduces relevant risks, while exposure control and an individual cat's circumstances still affect the practical protection plan.
Which cats should receive FeLV vaccination?
WSAVA's 2024 guidance treats FeLV vaccination as core where the disease occurs for cats younger than one year. It also treats the vaccine as core for older cats with outdoor exposure in those areas. This is a risk-based recommendation, not a universal instruction for every adult cat in every region.
An older cat with outdoor exposure has a different risk profile from a low-exposure adult in a low-prevalence area. WSAVA also says a cat's FeLV-negative status should be established before vaccination. FeLV vaccines protect against progressive infection and related disease, but they may not prevent every possible infection outcome. Before deciding, ask your veterinarian to assess:.
- The cat's age and current FeLV status
- Outdoor access and likely contact with other cats
- Whether FeLV disease occurs locally
- Upcoming changes in housing or exposure
- Which vaccine products and combinations are locally available
Does the new combination mean fewer appointments?
Not necessarily. For the five-pathogen HCPChFeLV vaccine, immunity begins about one week after vaccination. After the initial series, the stated duration is three years for panleukopenia but one year for FeLV, herpesvirus, calicivirus, and Chlamydia felis. That means "one shot protects for three years" would misrepresent the product.
A combination injection can contain components with different durations, so follow-up timing must account for each component and the cat's exposure risk. WSAVA supports core FVRCP revaccination no more often than every three years for low-risk adult cats. FVRCP covers feline viral rhinotracheitis associated with herpesvirus, calicivirus, and panleukopenia. Cats facing boarding or other high-exposure conditions may need herpesvirus and calicivirus revaccination as often as annually. Those components provide partial protection, and stress can weaken that protection.
What should owners watch next?
The next practical questions are whether either newly authorized product is available locally, which cats veterinarians consider suitable candidates, and how clinics integrate its unequal component durations into reminder schedules. Owners should also resist treating every new vaccine technology as evidence that all feline vaccine questions are settled.
The current evidence supports reduced disease or shedding for the authorized product's targets, not complete prevention in every vaccinated cat. Feline infectious peritonitis, or FIP, remains a separate watch-out. WSAVA does not recommend FIP vaccination for pet cats because evidence of clinically relevant protection is insufficient, and most cats old enough to receive it are already positive for coronavirus antibodies.